Exploring Associations between Human Milk Oligosaccharides and Growth, Body Composition and Obesity Risk in Infancy and Early Childhood
Exploring Associations between Human Milk Oligosaccharides and Growth, Body Composition and Obesity Risk in Infancy and Early Childhood
批准号:
9317205
负责人:
Lars Bode
金额:
$23.26万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-04 至 2019-07-31
关键词:
AddressAdolescenceAdultAffectBehavior TherapyBirthBody CompositionBody mass indexBreast FeedingCharacteristicsChild health careChildhoodComplexDataData SetDevelopmentDietDiet ModificationDiseaseEnvironmentEnvironmental ExposureEnvironmental Risk FactorEquationFatty acid glycerol estersGoalsGrowthHeightHome environmentHumanHuman MilkIndividualInfantKnowledgeLifeLongitudinal cohortMediatingMetabolicMilk BanksModelingMothersObesityOligosaccharidesOverweightPhenotypePlayPolysaccharidesPostpartum PeriodPredispositionPreventionProductionPublic HealthRecommendationResourcesRisk FactorsRoleSamplingShapesStatistical ModelsStressSupplementationTechnologyTestingWeightWeight GainWomanclinical Diagnosiscohortcritical perioddata miningdisorder preventionearly childhoodgut microbiomehigh throughput technologyinfancyinfant outcomeinter-individual variationmetabolic phenotypemuscle formnovel strategiesnutritionobesity in childrenobesity riskprebioticsstem
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT
Childhood obesity is a major public health challenge that often tracks into adulthood. Infancy and early
childhood (birth to 24 months) may be a critical period in the development of overweight and obesity, and early
nutrition may play an important role. Breastfeeding has a consistent protecting effect from obesity in childhood
and adolescence. However, which of the bioactive components in human milk contribute to the effect on infant
metabolic phenotype and growth remains mostly unknown. Human milk oligosaccharides (HMO) are a key
bioactive component of human milk. HMO act as human milk prebiotics and help shape a healthy infant gut
microbiome. An imbalance in the gut microbiome composition can have functional consequences that can
increase susceptibility for weight gain and/or metabolic complications. However, associations between HMO
composition and infant growth, body composition and obesity risk have not been studied. This gap in
knowledge stems primarily from a lack of suitable longitudinal cohorts to study these associations (i.e. with
available breast milk samples, precise clinical diagnoses, and detailed maternal phenotyping) and the absence
of technology for high-throughput HMO analysis required for large cohorts. Our proposed project will address
these deficiencies by pairing existing datasets and bio-banked milk samples from the Finnish mother-infant
STEPS cohort with new state-of-the-art technology for HMO analysis. HMO amount and composition are highly
variable between different women, and we hypothesize (1) that HMO composition in mother's milk is
associated with growth, body composition and obesity risk in infancy and early childhood, and (2) that maternal
factors influence HMO composition. To test these hypotheses, Aim 1 proposes to analyze inter-individual
variation in HMO composition in mother's milk and evaluate associations with growth, body composition and
overweight/obesity in 811 mother-infant dyads from the STEPS cohort. Aim 2 proposes to identify fixed and
modifiable maternal factors that influence HMO composition and apply structural equation modeling to
determine the direct and indirect effect of HMO on disease development. Leveraging resources from the
landmark STEPS study and using new high-throughput technology for HMO composition analysis provides a
unique and powerful opportunity to study the maternal determinants of HMO production and the effects of
HMO on child health. Discoveries from the proposed exploratory project will inform new approaches for
disease prevention, including (1) HMO supplementation strategies with the aim to add specific `protective'
HMO to an infant's diet to reduce the risk of obesity in infancy and early childhood, and (2) recommendations
on dietary or lifestyle modifications for breastfeeding mothers to `optimize' HMO composition and enrich
specific `protective' HMO.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Origins and Benefits of Biologically Active Components in Human Milk
-
批准号:10683486
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2023
-
负责人:Lars Bode
-
依托单位:
Milk Analytics Core
-
批准号:10487510
-
项目类别:
-
资助金额:$20.03万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
-
批准号:10681290
-
项目类别:
-
资助金额:$123.91万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Milk Analytics Core
-
批准号:10681304
-
项目类别:
-
资助金额:$20.26万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Exploring Associations between Human Milk Oligosaccharides and Atherosclerosis Risk Factors in Infancy and Early Childhood
-
批准号:10195374
-
项目类别:
-
资助金额:$22.6万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Exploring Associations between Human Milk Oligosaccharides and Atherosclerosis Risk Factors in Infancy and Early Childhood
-
批准号:10491367
-
项目类别:
-
资助金额:$17.17万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
-
批准号:10659295
-
项目类别:
-
资助金额:$101.57万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
-
批准号:10309708
-
项目类别:
-
资助金额:$125.0万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Milk Analytics Core
-
批准号:10309713
-
项目类别:
-
资助金额:$20.51万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
-
批准号:10487493
-
项目类别:
-
资助金额:$125.0万
-
财政年份:2021
-
负责人:Lars Bode
-
依托单位:
Exploring human milk oligosaccharides and malaria risk in breastfed infants
-
批准号:10226366
-
项目类别:
-
资助金额:$17.0万
-
财政年份:2020
-
负责人:Lars Bode
-
依托单位:
Exploring human milk oligosaccharides and malaria risk in breastfed infants
-
批准号:10057627
-
项目类别:
-
资助金额:$20.12万
-
财政年份:2020
-
负责人:Lars Bode
-
依托单位:
Exploring Oligosaccharide Synthesis in Human Mammary Gland Epithelial Cells
-
批准号:8892907
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2015
-
负责人:Lars Bode
-
依托单位:
Disialyl oligosaccharides as Necrotizing Enterocolitis therapeutics
-
批准号:9048196
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2015
-
负责人:Lars Bode
-
依托单位:
Selective Inhibitors of Plasmodium Falciparum G6PD as Novel Antimalarials
-
批准号:8632677
-
项目类别:
-
资助金额:$41.47万
-
财政年份:2014
-
负责人:Lars Bode
-
依托单位:
Selective Inhibitors of Plasmodium Falciparum G6PD as Novel Antimalarials
-
批准号:8911238
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2014
-
负责人:Lars Bode
-
依托单位:
Screening for Human Milk Oligosaccharides that Protect Infants from HIV Infection
-
批准号:8090034
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2010
-
负责人:Lars Bode
-
依托单位:
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis
-
批准号:8119080
-
项目类别:
-
资助金额:$24.65万
-
财政年份:2009
-
负责人:Lars Bode
-
依托单位:
Identification of G6PD inhibitors for the development of novel antimalarial drugs
-
批准号:7905094
-
项目类别:
-
资助金额:$23.34万
-
财政年份:2009
-
负责人:Lars Bode
-
依托单位:
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis
-
批准号:7924735
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2009
-
负责人:Lars Bode
-
依托单位:
海外基金